Cambridge Antibody Technology Group Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cambridge Antibody Technology Group

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jongmans who started this subject	11/19/2003 5:33:33 AM
From: nigel bates	Read Replies (2) of 625

Another potential fly in the ointment: Australia's Peptech: Resolves Dispute With Abbott Tuesday November 18, 6:18 pm ET MELBOURNE -(Dow Jones)- Australian biotechnology company Peptech Ltd. said Wednesday it has resolved a licensing dispute with Abbott Laboratories (NYSE:ABT - News) Inc. (ABT). Terms of the agreement weren't disclosed in the statement sent to the stock exchange, but Peptech said the confidential resolution is expected to be finalized in the coming weeks and is subject to final approval by both companies. Abbott had previously claimed that its sale of the Humira drug, a treatment for rheumatoid arthritis, didn't infringe licensed Peptech patents....

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next